MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...

A survey of senior figures in European biopharma companies has found that dealmaking and M&A are expected to increase, with ...

Wegovy has since been joined in the UK market by Eli Lilly's oral GLP-1 agonist Foundayo (orforglipron), which was approved by the MHRA in August. Neither product is covered by the NHS, but can be ...

Klick Health's recent acquisition of Oxford PharmaGenesis reflects that shift. “Clearly for a lot of reasons that have been ...

Day One Strategy’s second annual AI in Pharma State of Play report – Are Insights leaders seeing real commercial value from AI adoption yet? – addresses the challenges Pharma Insights teams are facing ...

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis (MS) after a priority review by the US regulator. Tolebrutinib ...

Summit Therapeutics has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to show an improvement in overall survival in a lung cancer trial. New ...

Lundbeck has announced a major change to its commercial strategy, withdrawing from 27 markets and handing day-to-day operations to partner companies. The move – described as a "sharpening" of ...

It’s been almost a decade since Japanese pharma company Daiichi Sankyo began its dramatic pivot from cardiovascular health into antibody-drug conjugates. For Daiichi Sankyo, it’s hard to argue that ...

AstraZeneca's baxdrostat has hit the mark in another phase 3 trial involving people who struggle to control their blood pressure with current therapies, keeping the would-be blockbuster on track for ...

Reports are emerging that a multibillion-dollar partnership between AbbVie and Alphabet-backed biotech Calico has come to an end after more than a decade. The divorce – first report by Stat – comes ...

Among the highlights of WCLC are final overall survival (OS) data from AstraZeneca's FLAURA 2 study of EGFR inhibitor Tagrisso (osimertinib) given in combination with chemotherapy as a first-line ...